Literature DB >> 32165279

Comparison of Preliminary clinical outcomes between percutaneous endoscopic and minimally invasive transforaminal lumbar interbody fusion for lumbar degenerative diseases in a tertiary hospital: Is percutaneous endoscopic procedure superior to MIS-TLIF? A prospective cohort study.

Shengxiang Ao1, Wenjie Zheng1, Junlong Wu1, Yu Tang1, Chao Zhang1, Yue Zhou2, Changqing Li3.   

Abstract

BACKGROUND: Percutaneous endoscopic transforaminal lumbar interbody fusion (PETLIF) has been used in the treatment of lumbar degenerative diseases, as a novel minimally invasive technique.
OBJECTIVES: To compare the surgical trauma and the medium-short term postoperative outcomes of PETLIF and traditional minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF).
METHODS: From April to August of 2018, 75 patients with lumbar degenerative diseases received PETLIF (Group PE, 35 cases) or MIS-TLIF (Group MIS, 40 cases) were enrolled in the prospective cohort study. We recorded the serum creatine kinase (CK) and C-reactive protein (CRP), blood loss, visual analog scale (VAS), Oswestry Disability Index (ODI), modified Macnab criteria score, complications, and fusion rates of the 2 groups.
RESULTS: There were significant reductions in CRP (P = 0.002) on postoperative day (POD) 3, and CK (P = 0.011) on POD 1 for Group PE than Group MIS. The mean true total blood loss (P < 0.001), intraoperative blood loss (P < 0.001), postoperative drains (P < 0.001), and hidden blood (P = 0.020) in the Group PE were significantly less compared with Group MIS. The VAS score for low-back pain, leg pain and ODI score improved significantly in both groups after surgery (P < 0.05). The VAS of low-back pain on POD 1 was significant less (P < 0.001) for Group PE. There was no statistical difference (P = 0.561) in CT fusion rates between Group PE (85%) and Group MIS (92%). No serious complication was observed in any patients.
CONCLUSION: The study indicated that PETLIF had advantages of less surgical trauma, less postoperative low-back pain, less hidden blood loss, and faster recovery, compared with MIS-TLIF. There was no significant difference in medium-short term surgical outcomes between the 2 techniques. However, the indications of PETLIF is relatively limited, and the learning curve of PETLIF is deep, surgeons need to select indications strictly. Further study with big sample size and long-term follow-up is needed.
Copyright © 2020 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  C-reactive protein; Clinical outcome; Creatine kinase; Hidden blood loss; Minimally invasive transforaminal lumbar interbody fusion; Percutaneous endoscopic transforaminal lumbar interbody fusion

Mesh:

Year:  2020        PMID: 32165279     DOI: 10.1016/j.ijsu.2020.02.043

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  22 in total

1.  Application of electromagnetic navigation in endoscopic transforaminal lumbar interbody fusion: a cohort study.

Authors:  Hao Zhang; Derong Xu; Chao Wang; Kai Zhu; Jianwei Guo; Chong Zhao; Jialuo Han; Houchen Liu; Xuexiao Ma; Chuanli Zhou
Journal:  Eur Spine J       Date:  2022-06-24       Impact factor: 2.721

Review 2.  [Analysis of technical advantages and disadvantages of percutaneous endoscopic lumbar interbody fusion and its trend prospect].

Authors:  Bin Zhang; Qingquan Kong; Limin Rong
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2022-06-15

3.  [Comparison of effectiveness between percutaneous coaxial large-channel endoscopic lumbar interbody fusion and minimal invasive transforaminal lumbar interbody fusion in treatment of degenerative lumbar spinal stenosis].

Authors:  Junlin Liu; Qingquan Kong; Pin Feng; Bin Zhang; Junsong Ma; Yuan Hu; Xi Wu; Xiang Shu; Congmin Pu
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2022-06-15

4.  [Clinical study on real-time three-dimensional CT navigation-guided full-endoscopic lumbar interbody fusion].

Authors:  Yang Yang; Jianwen Dong; Zhongyu Liu; Ruiqiang Chen; Zihao Chen; Zhengjia Zhai; Jiakun Qi; Limin Rong
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2022-06-15

5.  Full Endoscopic Posterolateral Transarticular Lumbar Interbody Fusion Using Transparent Plastic Working Tubes: Technical Note and Preliminary Clinical Results.

Authors:  Yu Du; Fuling Jiang; Haiyan Zheng; Xudong Yao; Zhengjian Yan; Yang Liu; Liyuan Wang; Xintai Zhang; Liang Chen
Journal:  Front Surg       Date:  2022-06-13

6.  Radiation Dose Reduction and Surgical Efficiency Improvement in Endoscopic Transforaminal Lumbar Interbody Fusion Assisted by Intraoperative O-arm Navigation: A Retrospective Observational Study.

Authors:  Junfeng Gong; Xinle Huang; Liwen Luo; Huan Liu; Hao Wu; Ying Tan; Changqing Li; Yu Tang; Yue Zhou
Journal:  Neurospine       Date:  2022-06-30

7.  Comparison of Postoperative Outcomes Between Percutaneous Endoscopic Lumbar Interbody Fusion and Minimally Invasive Transforaminal Lumbar Interbody Fusion for Lumbar Spinal Stenosis.

Authors:  Lu Lin; Xiao-Qin Liu; Lei Shi; Si Cheng; Zhi-Qiang Wang; Qi-Jun Ge; Ding-Zhi Gao; Amadou Cheffou Ismail; Zhen-Yong Ke; Lei Chu
Journal:  Front Surg       Date:  2022-06-15

8.  A Narrative Review of Uniportal Endoscopic Lumbar Interbody Fusion: Comparison of Uniportal Facet-Preserving Trans-Kambin Endoscopic Fusion and Uniportal Facet-Sacrificing Posterolateral Transforaminal Lumbar Interbody Fusion.

Authors:  Hyeun Sung Kim; Pang Hung Wu; Koichi Sairyo; Il-Tae Jang
Journal:  Int J Spine Surg       Date:  2021-12

9.  Initial Experience With a Full Endoscopic Facet Fusion in Combination With Endoscopic Interbody Fusion.

Authors:  Jacques Lara-Reyna; Konstantinos Margetis
Journal:  Cureus       Date:  2021-04-06

10.  How Much Benefit Can Patients Acquire from Enhanced Recovery After Surgery Protocols with Percutaneous Endoscopic Lumbar Interbody Fusion?

Authors:  Junfeng Gong; Liwen Luo; Huan Liu; Changqing Li; Yu Tang; Yue Zhou
Journal:  Int J Gen Med       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.